Γρηγόρης Παπαγρηγορίου

Dr Papagregoriou is the lead scientist and a group leader at the biobank.cy CoE, UCY, where he has the responsibility to oversee, facilitate, and report on the successful implementation of research activities proposed in the CY-Biobank TEAMING project. He was appointed by the director of the CoE as a member of the Academic Council and is also a member of the internal bioethics advisory board. He received his BSc in Biology at the Aristoteles University, Greece and his MRes degree in Medical and Molecular Biosciences with distinction from the Medical School of the University of Newcastle, UK. Dr Papagregoriou obtained a PhD in Molecular Biology from UCY in 2012 with full scholarship and gained an award for demonstrating outstanding academic and research performance upon his graduation. He works with ADTKD-MUC1 patients in Cyprus since 2006. He served as a research scientist at the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard, MA, USA at the Kidney Disease Initiative, leading ADTKD-MUC1 biomarker discovery and implemented the first biomarker clinical trial in Cyprus. His group focuses on uEV multi-omics biomarker discovery, the use of AI in modelling disease progression to predict outcomes, genetics of rare kidney diseases, assay development, formation of nanoparticles as drug delivery vehicles, and the development of more relevant, tubular disease in vitro models.